By inhibiting VEGF and other pro-angiogenic factors, PI3K inhibitors disrupt the delicate balance between stimulators and inhibitors of angiogenesis, thereby inhibiting the formation of new blood vessels required for tumor growth and progression. This evidence concerns the gene PIK3CG and neoplasm.